“…There were 11 cost effectiveness analyses (CEAs) [26, 28-33, 35, 40-42] and three cost utility analyses (CUAs) [25,36,38], with the remaining nine studies a combination of both CEA and CUA [24,27,34,37,39,[43][44][45][46]. For the CEAs, the most common clinical outcome related to percentage of patients healed (12 outcomes) [26,27,30,32,33,37,39,[41][42][43][44][45], with time taken for the ulcer to heal used as an outcome in ten studies [24, 25, 29, 31, 34-36, 41, 42, 46], and reduction in wound area size used twice [28,29]. It should be noted that whilst these outcome measures may be clinically meaningful within VLUs, they do not have a willingness-to-pay threshold attached to them [such as with the quality-adjusted life-year (QALY)], and they do not facilitate comparison with other economic evaluations conducted within other disease areas.…”